• June 16-19, 2025
  • Boston Convention & Exhibition Center

Sessions

Loading

GeneVentiv Therapeutics, Inc.

Wednesday, June 05, 2024
Company Presentation
Cell and Gene Therapy and Genome Editing
Company Presentation Theater 1
GeneVentiv Therapeutics is a pre-clinical gene therapy company focused on blood diseases and disorders. Our lead program, GENV-HEM, is the first AAV-based gene therapy to treat 33% of hemophilia patients (50K developed world) with neutralizing antibodies (inhibitors) to their missing clotting factor. GENV-HEM is also the first universal gene therapy for hemophilia, which has received Orphan Drug Designation from the FDA for Hemophilia A and B with or without inhibitors and a Letter of Support from the National Bleeding Disorders Foundation.
GeneVentiv Therapeutics, Inc.
Company Website: http://www.geneventiv.com
Lead Product in Development: GENV-HEM, is the first, single infusion, AAV-based gene therapy to treat 33% of hemophilia patients with neutralizing antibodies (inhibitors) to their missing clotting factor (50K developed world patients). GENV-HEM is also the first universal gene therapy for all hemophilias, has received Orphan Drug Designation from the FDA for Hemophilia A and B with or without inhibitors and a Letter of Support from the National Bleeding Disorders Foundation.

Company HQ City

Raleigh

Company HQ State

NC

Company HQ Country

United States

CEO/Top Company Official

Damon R. Race

Development Phase of Primary Product

Pre-Clinical
Primary Speaker
Damon Race, MBA
CEO
GeneVentiv Therapeutics, Inc.
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS